8月28日周四盘中，博安生物（06955.HK）股价大跌5.22%，引发市场关注。
消息面上，博安生物于8月27日晚间发布2025年中期业绩报告。数据显示，公司截至2025年6月30日的六个月内，实现收入3.93亿元人民币，同比增长8.39%；但股东应占溢利仅为2051.4万元人民币，同比大幅下降66.74%。每股基本盈利为0.04元人民币。
值得注意的是，尽管博安生物的收入有所增长，主要得益于其主要产品（博优诺®、博优倍®及博洛加®）销售较去年同期增长15.9%至3.85亿元，但净利润的大幅下滑引发了投资者的担忧。公司未公布具体的利润下滑原因，但市场分析认为，可能与运营成本增加或者研发投入加大有关。此外，公司连续多个财报期未派息的情况也可能影响了投资者信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.